Tennessee Code Title 71. Welfare § 71-5-199c

(1) “Biomarker” has the same meaning as defined in § 56-7-2369;

(2) “Biomarker testing” has the same meaning as defined in § 56-7-2369;

(3) “Health benefit plan” means health insurance coverage as defined in § 56-7-109;

(4) “Health insurer” means a health insurance entity as defined in § 56-7-109;

(5) “Nationally recognized clinical practice guideline” has the same meaning as defined in § 56-7-2369;  and

(6) “TennCare health benefit plan” means a health benefit plan issued by a health insurer pursuant to an agreement with the bureau of TennCare to provide health insurance coverage for an enrollee in the medical assistance program.

(1) Labeled indications for a federal food and drug administration (FDA)-approved or FDA-cleared test;

(2) Indicated tests for an FDA-approved drug;

(3) Warnings and precautions on FDA-approved drug labels;

(4) Centers for medicare and medicaid services national coverage determinations or medicare administrative contractor local coverage determinations;  or

(5) Nationally recognized clinical practice guidelines.

(h)(1) The commissioner of commerce and insurance shall compile a report on the usage of covered biomarker testing and cost savings generated pursuant to this section, based upon data reported to the department of commerce and insurance by health insurers.

(2) The commissioner may establish reporting standards by rule for the purpose of compiling data necessary to complete the report required by this subsection (h).  The rules must be promulgated in accordance with the Uniform Administrative Procedures Act, compiled in title 4, chapter 5.

(3) No later than February 1, 2029, the commissioner shall deliver a copy of the report to the chief clerk of the senate, the chief clerk of the house of representatives, and the legislative librarian.  The report may be delivered by electronic means.